Patents by Inventor Cornelis Erik Hack
Cornelis Erik Hack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220220179Abstract: The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.Type: ApplicationFiled: March 14, 2022Publication date: July 14, 2022Inventors: Niels EIJKELKAMP, Cornelis Erik HACK, Judith PRADO SANCHEZ, Jelena POPOV-CELEKETIC, Sabine VERSTEEG
-
Publication number: 20220143145Abstract: The present invention relates to a compound comprising (1) a first binding moiety that binds to an Interleukin 4 receptor; and (2) a second binding moiety that binds to a cytokine receptor (e.g., an Interleukin 10 receptor, Interleukin 13 receptor, interleukin 27 receptor, interleukin 33 receptor, or transforming growth factor beta 1/2 receptor). Compounds of the disclosure cluster or crosslink the IL4 receptor and a cytokine receptor, and surprisingly, elicit unique responses in the nervous system, including unique signaling and gene expression profiles. The signaling and gene expression profiles generated IL4-cytokine fusion proteins of the disclosure are distinct from those observed in response to the combination of IL4 and the cytokine, and contribute to the superior therapeutic effects over the combination of the component parts.Type: ApplicationFiled: October 18, 2021Publication date: May 12, 2022Inventors: Niels EIJKELKAMP, Cornelis Erik HACK, Judith PRADO SANCHEZ, Remco Henri Sebastiaan WESTERINK, Kris Alan REEDQUIST, Leendert KOENDERMAN
-
Patent number: 11312757Abstract: The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.Type: GrantFiled: January 26, 2021Date of Patent: April 26, 2022Assignee: Synerkine Pharma B.V.Inventors: Niels Eijkelkamp, Cornelis Erik Hack, Judith Prado Sanchez, Jelena Popov-{hacek over (C)}eleketić, Sabine Versteeg
-
Publication number: 20210261639Abstract: The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: ApplicationFiled: March 4, 2021Publication date: August 26, 2021Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
-
Publication number: 20210214411Abstract: The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.Type: ApplicationFiled: January 26, 2021Publication date: July 15, 2021Inventors: Niels EIJKELKAMP, Cornelis Erik HACK, Judith PRADO SANCHEZ, Jelena POPOV-CELEKETIC, Sabine VERSTEEG
-
Patent number: 11059905Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.Type: GrantFiled: March 23, 2017Date of Patent: July 13, 2021Assignee: Prothix B.V.Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
-
Patent number: 10981964Abstract: The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: GrantFiled: December 9, 2019Date of Patent: April 20, 2021Assignee: Synerkine Pharma B.V.Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
-
Patent number: 10851143Abstract: The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: GrantFiled: December 14, 2017Date of Patent: December 1, 2020Assignee: Synerkine Pharma B.V.Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
-
Patent number: 10717785Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.Type: GrantFiled: February 23, 2018Date of Patent: July 21, 2020Assignee: BROTEIO PHARMA B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Publication number: 20200147178Abstract: The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: ApplicationFiled: December 9, 2019Publication date: May 14, 2020Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
-
Publication number: 20190106509Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.Type: ApplicationFiled: March 23, 2017Publication date: April 11, 2019Applicant: Prothix B.V.Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
-
Publication number: 20180319895Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.Type: ApplicationFiled: February 23, 2018Publication date: November 8, 2018Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Patent number: 9944717Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.Type: GrantFiled: May 22, 2014Date of Patent: April 17, 2018Assignee: Broteio Pharma B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Publication number: 20180094037Abstract: The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: ApplicationFiled: December 14, 2017Publication date: April 5, 2018Applicant: UMC Utrecht Holding B.V.Inventors: Joel Adrianus Gijsbert VAN ROON, Sarita Aimee Yvonne HARTGRING, Cornelis Erik HACK, Christina LOUWS, Floris Paulus Jacobus Gerardus LAFEBER
-
Publication number: 20160108134Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.Type: ApplicationFiled: May 22, 2014Publication date: April 21, 2016Inventors: CORNELIS ERIK HACK, CAFER YILDIZ, LOUIS BOON, PETRUS JOHANNES SIMONS
-
Publication number: 20140356377Abstract: The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by excessive bleeding, such as surgery, trauma and internal bleeding. The inhibitor of antithrombin III can e.g. a peptide, an aptamer or an antibody or antibody fragment that specifically binds to and inhibits antithrombin III.Type: ApplicationFiled: February 24, 2012Publication date: December 4, 2014Applicant: UMC Utrecht Holding B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz
-
Publication number: 20140314712Abstract: The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.Type: ApplicationFiled: November 8, 2012Publication date: October 23, 2014Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
-
Patent number: 8835119Abstract: The invention refers to an in vitro method of functionally determining at physiological conditions deficiencies in the lectin pathway of the complement system, the method comprising the steps of (a) providing a sample of mammalian blood, serum, plasma or another body fluid; (b) preventing in the sample the activation of the classical pathway by contacting the sample with an inhibitor of a molecule of the C1 complex of the complement system; (e) preventing in the sample the activation of the alternative pathway; (d) activating the lectin pathway in the sample; and (e) determining in the sample any activation of the autologous C5b-9 complex.Type: GrantFiled: July 11, 2003Date of Patent: September 16, 2014Assignee: Euro Diagnostica ABInventors: Johanna Roos, Mohamed R. Daha, Lee H. Bouwman, Cornelis Erik Hack
-
Patent number: 6723524Abstract: An immunoassay, e.g. ELISA, method and kit for determining (preferably quantitatively) an analyte adsorbed at a surface or present in a liquid sample, comprising binding the analyte to a solid phase, attaching a marker to the analyte, and detecting marker attached to the solid-phase. The invention proposes to use a combination of marker and detection (e.g. an enzyme-substrate combination) which is capable of producing a precipitate on a solid phase which carries the marker and to detect the binding of analyte to the solid phase by in-situ determining the change in surface mass of the solid phase due to the formation of the precipitate. Ellipsometry is an example of a technique suitable for determining the change of surface mass of the solid phase, which could be made of a silicon- or chromium-sputtered glass slide The invention shortens the assay time and/or improves the assay sensitivity, and allows to measure extremely low surface concentrations of analytes of interest.Type: GrantFiled: May 31, 2000Date of Patent: April 20, 2004Assignee: Nederlandse Organisatie voor toegepastnatuurwetenschappelijk Onderzoek TNOInventors: Willem Theodoor Hermens, Markus Robers, Cornelis Erik Hack, Lucien Adrianus Aarden
-
Publication number: 20040067533Abstract: This invention relates to the field of prion diseases. A method is provided to reduce false positive outcomes in a test by monitoring the activity of a proteolytic enzyme in a test sample comprising providing the test sample with a substrate and contacting the enzyme with said substrate to allow conversion of the substrate by the enzyme into a detectable product and detecting said product. Use of a method according to the invention can improve the reliability of prion tests.Type: ApplicationFiled: July 15, 2003Publication date: April 8, 2004Inventors: Josephus Wilhelmus, A., M. van Oers, Teun Jan, K. van der Vorst, Cornelis Erik Hack, Franciscus Antonius C. Engelenburg